JAMDA
Volume 8, Issue 8 , Pages 489-492 , October 2007

Update on Diabetes in the Elderly and the Application of Current Therapeutics

  • Angela D. Mazza, DO
    • ,
  • John E. Morley, MB, BCh

      Affiliations

    • Corresponding Author InformationAddress correspondence to John E. Morley, MB, BCh, Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Boulevard, M238, St Louis, MO 63104.

References 

  1. Morley JE. Diabetes mellitus: A major disease of older persons. J Gerontol A Biol Sci Med Sci. 2000;55:M255–M256
  2. Zarowitz BJ, Tangalos EG, Hollenack K, O’Shea T. The application of evidence-based principles of care in older persons (issue 3): Management of diabetes mellitus. J Am Med Dir Assoc. 2006;7:234–240
  3. McNabney MK, Pandya N, Iwuagwu C, et al. Differences in diabetes management of nursing home patients based on functional and cognitive status. J Am Med Dir Assoc. 2005;6:375–382
  4. Meyers R, Broton JC, Woo-Rippe KW, et al. Variability in glycosylated hemoglobin values in diabetic patients living in long-term care facilities. J Am Med Dir Assoc. 2007;8:511–514
  5. Haas L. Optimizing insulin use in Type 2 diabetes: role of basal and prandial insulin in long-term care facilities. J Am Med Dir Assoc. 2007;8:502–510
  6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2006;29:59;42
  7. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 2002. Diabetes Care. 2003;26:917–932
  8. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002–3008
  9. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–524
  10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  11. Saydah S. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes mellitus. JAMA. 2004;291:335–342
  12. Stratmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults. Arch Intern Med. 2005;165:1612–1617
  13. Volpato S, Leveille , Blaum C, et al. Risk factors of falls in older disabled women with diabetes: The Women’s Health and Aging Study. J Gerontol. 2005;60A:1539–1545
  14. Rodríguez-Saldańa J, Morley JE, Reynoso MT, et al. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc. 2002;50:111–116
  15. Miller DK, Lui LY, Perry HM, et al. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci. 1999;54:M230–M236
  16. Roberts SB, Hajkuk CL, Howarth NC, et al. Dietary variety predicts low body mass index and inadequate macronutrient and micronutrient intakes in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2005;60:613–621
  17. Rosenthal MJ, Fajardo M, Gilmore S, et al. Hospitalization and mortality of diabetes in older adults (A 3-year prospective study). Diabetes Care. 1998;21:231–235
  18. Levenson SA, Morley JE. Evidence rocks in long-term care, but does it roll?. J Am Med Dir Assoc. 2007;8:493–501
  19. American Diabetes Association. Evidence-based nutrition principles and recommendation for the treatment and prevention of diabetes and related complication. Diabetes Care. 2002;25:202–212
  20. American Diabetes Association. Nutrition recommendations and interventions for diabetes—2006. Diabetes Care. 2006;29:2140–2157
  21. Morley JE, Kim MJ, Haren MT, et al. Frailty and the aging male. Aging Male. 2005;8:135–140
  22. MacIntosh C, Morley JE, Chapman IM. The anorexia of aging. Nutrition. 2000;16:983–995
  23. Morley JE. Weight loss in the nursing home. J Am Med Dir Assoc. 2007;8:201–204
  24. Tariq SH, Karcic E, Thomas DR, et al. The use of no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc. 2001;101:1463–1466
  25. Coulston AM, Mandelbaum D, Reaven GM. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1990;51:67–71
  26. Wedick NM, Barrett-Connor E, Knoke JD, Wingard DL. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: The Rancho Bernardo Study. J Am Geriatr Soc. 2002;50:1810–1815
  27. American Diabetes Association. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care. 2007;30(Suppl 1):S48–S65
  28. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetes Care. 2004;27:2518–2537
  29. Schwartz RS. Exercise training in treatment of diabetes mellitus in elderly patient. Diabetes Care. 1990;13(Suppl 2):77–85
  30. Castaneda C, Layne JE, Munoz-Orians L, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002;25:2335–2341
  31. Dunstan DW, Daly RM, Owen N, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002;25:1729–1736
  32. Mazza AD, Morley JE. Metabolic syndrome in the older male population. Aging Male. 2007;10:3–8
  33. Banks WA, Willoughby LM, Thomas DR, Morley JE. Insulin resistance syndrome in the elderly: Assessment of functional, biochemical, metabolic, and inflammatory status. Diabetes Care. 2007;29:[Epub ahead of print].
  34. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947–953
  35. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998–1007
  36. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096–1105
  37. Marfella R, D’Amico M, Di Filippo C, et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: Effects of rosiglitazone treatment. J Am Coll Cardiol. 2006;47:2444–2455
  38. Cicero DG, D’Angelo A, Gaddi A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial. Clin Ther. 2006;28:679–688
  39. Nissen NE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  40. Home PD, Pocock ST, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med. 2007;28–38
  41. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:981–988
  42. Hvidberg A, Nielsen MT, Hilsted J, et al. Effect of glucagon-like peptide 1 (proglucagon 78–107 amide) on hepatic glucose production in healthy men. Metabolism. 1994;43:104–108
  43. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:848–856
  44. Flint A, Raben A, Astrup A, Jolst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–520
  45. Meneilly GS, Veldhuis JD, Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;90:6251–6256
  46. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282–1290
  47. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77–88
  48. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100
  49. Buse JB, Henry RR, Han J, et al. Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635
  50. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091
  51. Kim D, MacDonell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2006;30:1487–1493
  52. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875
  53. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56:1475–1480
  54. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141–151
  55. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Ther. 2005;78:675–688
  56. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205
  57. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–335
  58. DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–106
  59. Gentilcore D, Bryant B, Wishart JM, et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med. 2005;118:1289
  60. Morley JE. Postprandial hypotension—the ultimate Big Mac Attack [editorial]. J Gerontol A Biol Sci Med Sci. 2001;56:M741–M743
  61. Kim MJ, Rolland Y, Cepeda O, et al. Diabetes mellitus in older men. Aging Male. 2006;9:139–147
  62. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47–53
  63. Morley JE, Flood JF. Effect of competitive antagonism of NO synthetase on weight and food intake in obese and diabetic mice. Am J Physiol. 1994;266(1 Pt 2):R164–R168
  64. Kumar VB, Bernardo AE, Vyas K, et al. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci. 2001;69:2789–2799
  65. Alam T, Weintraub N, Weinreb J. What is the proper use of hemoglobin A1C monitoring in the elderly?. J Am Med Dir Assoc. 2006;7(3 Suppl):S60–S64
  66. Morley JE. The elderly Type 2 diabetic patient: Special considerations. Diabet Med. 1998;15(Suppl 4):S41–S46

 Dr. Morley’s conflict of interest statement can be viewed on the JAMDA website at: http://www.journals.elsevierhealth.com/periodicals/jmda/content/conflictsofinterest

PII: S1525-8610(07)00346-5

doi: 10.1016/j.jamda.2007.07.007

JAMDA
Volume 8, Issue 8 , Pages 489-492 , October 2007

Article Tools